An in-depth analysis of the side effects of Selinisol targeted drugs

Selinexor (Selinexor), the first oral export protein inhibitor, has been approved in combination with dexamethasone (Sd) to provide a new treatment option for patients with grade III refractory myeloma (PTS) who have undergone heavy pretreatment. At the same time, it is also combined with bortezomib and dexamethasone (SVd) to bring hope to patients with 1-3 relapsed/refractory myeloma (RRMM). The drug is unique in that it precisely targets the intracellular nuclear transport protein XPO1.

The use of selinesol is not without risks. In clinical use, it has been observed to be associated with a range of side effects, primarily affecting patients' gastrointestinal health, appetite, and overall fatigue. Specifically, nausea, vomiting, diarrhea, and loss of appetite are the most commonly reported side effects during initial treatment with selinexol. These reactions usually occur in the early stages after treatment is initiated, but fortunately, most patients are able to alleviate these symptoms with appropriate care and lifestyle modifications.

In addition to these common side effects, selinesol may cause some more serious reactions. Among them, blood-related side effects are of particular concern. Patients may suffer from thrombocytopenia, anemia, leukopenia, etc. These problems will not only affect the patient's health, but may also increase the risk of infection. Therefore, while using selinexol, doctors usually recommend that patients have regular blood tests so that these potential side effects can be detected and dealt with in a timely manner.

Overall, although selinexol provides a new treatment option for myeloma patients as an effective targeted drug, it does have a certain risk of side effects during its use.